Aratana Therapeutics Company Profile (NASDAQ:PETX)

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PETX
  • CUSIP: N/A
  • Web:
  • Market Cap: $266.18 million
  • Outstanding Shares: 43,001,000
Average Prices:
  • 50 Day Moving Avg: $5.87
  • 200 Day Moving Avg: $6.17
  • 52 Week Range: $4.97 - $10.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.64
  • P/E Growth: -0.37
Sales & Book Value:
  • Annual Revenue: $9.28 million
  • Price / Sales: 27.80
  • Book Value: $2.36 per share
  • Price / Book: 2.54
  • EBIDTA: ($50,680,000.00)
  • Net Margins: -642.93%
  • Return on Equity: -51.21%
  • Return on Assets: -32.34%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 4.24%
  • Quick Ratio: 3.94%
  • Average Volume: 303,700 shs.
  • Beta: 3.43
  • Short Ratio: 13.91

Frequently Asked Questions for Aratana Therapeutics (NASDAQ:PETX)

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics, Inc. (NASDAQ:PETX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business earned $5.16 million during the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The company's revenue for the quarter was down 86.4% on a year-over-year basis. During the same period last year, the company earned $0.61 EPS. View Aratana Therapeutics' Earnings History.

When will Aratana Therapeutics make its next earnings announcement?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Aratana Therapeutics.

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?

4 equities research analysts have issued 1-year target prices for Aratana Therapeutics' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Aratana Therapeutics' share price to reach $8.33 in the next year. View Analyst Ratings for Aratana Therapeutics.

What are analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "Q4'16 results uneventful. The Nocita and Galliprant launches are progressing and Entyce is on track for late '17 launch. However, we think the sell-off on the Q4 results was primarily driven by concerns around the cash runway and how this will be addressed. We like the risk/ reward at this level and reiterate our Buy rating. PT lowered to $8 (from $11)." (3/16/2017)
  • 3. Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:

  • Wendy L. Yarno, Chairman of the Board
  • Steven St. Peter M.D., President, Chief Executive Officer, Director
  • Craig A. Tooman, Chief Financial Officer, Treasurer
  • Brent Standridge, Chief Operating Officer
  • Ernst Heinen Ph.D., Chief Development Officer
  • Laura A. Brege, Independent Director
  • David L. Brinkley, Independent Director
  • Robert Benthall Gerber Jr., Independent Director
  • Irvine O. Hockaday Jr. Esq., Independent Director
  • Merilee Raines, Independent Director

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (15.84%), Broadfin Capital LLC (12.06%), Vanguard Group Inc. (5.06%), Janus Henderson Group PLC (4.16%), AWM Investment Company Inc. (3.69%) and General American Investors Co. Inc. (1.63%). Company insiders that own Aratana Therapeutics stock include Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Goldman Sachs Group Inc., TIAA CREF Investment Management LLC, Vanguard Group Inc., Capital Fund Management S.A., Mariner Wealth Advisors LLC and New York State Common Retirement Fund. Company insiders that have sold Aratana Therapeutics stock in the last year include Ernst Heinen and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Broadfin Capital LLC, Franklin Resources Inc., AWM Investment Company Inc., Dimensional Fund Advisors LP, Grandeur Peak Global Advisors LLC, PDT Partners LLC and Williams Jones & Associates LLC. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of Aratana Therapeutics stock can currently be purchased for approximately $6.00.

MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.33 (38.89% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/25/2017Lake Street CapitalLower Price TargetBuy -> Buy$15.00 -> $10.00LowView Rating Details
8/4/2017Jefferies Group LLCSet Price TargetBuy$8.00HighView Rating Details
5/10/2017Stifel NicolausLower Price TargetBuy -> Buy$8.00 -> $7.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00N/AView Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00N/AView Rating Details
11/4/2015Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $15.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Aratana Therapeutics (NASDAQ:PETX)
Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Earnings History by Quarter for Aratana Therapeutics (NASDAQ PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.24)N/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
2017 EPS Consensus Estimate: ($1.11)
2018 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.35)($0.29)($0.31)
Q2 20173($0.33)($0.28)($0.30)
Q3 20173($0.30)($0.24)($0.26)
Q4 20173($0.27)($0.21)($0.24)
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.03)($0.03)($0.03)
Q4 20181($0.03)($0.03)($0.03)
Q1 20191($0.12)($0.12)($0.12)
Q2 20191($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)


Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aratana Therapeutics (NASDAQ:PETX)
Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 73.04%
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aratana Therapeutics (NASDAQ:PETX)
Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline logo-$0.26 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter - September 21 at 6:22 AM logoAratana Therapeutics, Inc. (PETX) Insider Ernst Heinen Sells 10,000 Shares - September 19 at 8:08 PM logoAratana Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference - September 19 at 6:28 AM logoETFs with exposure to Aratana Therapeutics, Inc. : September 12, 2017 - September 12 at 8:30 AM logoAratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 - September 9 at 7:17 AM logoAratana Therapeutics Is A Lucrative Investment - Again - Seeking Alpha - September 8 at 7:03 AM logoAratana Therapeutics, Inc. (PETX) Stock Rating Lowered by ValuEngine - September 2 at 6:20 PM logoAratana Therapeutics, Inc. (PETX) Given Consensus Rating of "Hold" by Brokerages - September 2 at 2:38 PM logoLake Street Capital Cuts Aratana Therapeutics, Inc. (PETX) Price Target to $10.00 - August 25 at 9:42 AM logoAratana Therapeutics Looks Promising With Growing Revenue ... - Seeking Alpha - August 22 at 5:09 AM logo Analysts Expect Aratana Therapeutics, Inc. (PETX) Will Post Quarterly Sales of $5.77 Million - August 17 at 8:04 AM logoQ3 2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By Jefferies Group (PETX) - August 17 at 8:04 AM logoAnalysts Set Expectations for Aratana Therapeutics, Inc.'s FY2021 Earnings (PETX) - August 16 at 3:22 PM logo-$0.27 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter - August 15 at 4:08 AM logoFast 50 CEOs talk about their different paths to rapid growth - August 12 at 6:48 AM logoWilliam Blair Analysts Lift Earnings Estimates for Aratana Therapeutics, Inc. (PETX) - August 9 at 7:44 AM logoAratana Therapeutics, Inc. (PETX) Given Consensus Rating of "Hold" by Analysts - August 8 at 2:44 PM logoAratana Therapeutics, Inc. (PETX) to Post FY2020 Earnings of $0.83 Per Share, William Blair Forecasts - August 8 at 1:06 PM logoAratana Therapeutics' (PETX) CEO Steven St. Peter on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 6 at 1:35 AM logoJefferies Group LLC Reiterates $8.00 Price Target for Aratana Therapeutics, Inc. (PETX) - August 5 at 9:36 AM logoEdited Transcript of PETX earnings conference call or presentation 4-Aug-17 12:30pm GMT - August 5 at 6:05 AM logoAratana Therapeutics Reports Second Quarter 2017 Financial Results - August 4 at 6:54 AM logoAratana reports 2Q loss - August 4 at 6:54 AM logoAratana Therapeutics, Inc. (PETX) Announces Quarterly Earnings Results - August 3 at 10:02 PM logoAratana Therapeutics, Inc. (NASDAQ:PETX) Expected to Post Quarterly Sales of $4.60 Million - July 29 at 7:21 AM logoFY2019 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX) - July 28 at 7:24 PM logo Brokerages Anticipate Aratana Therapeutics, Inc. (NASDAQ:PETX) to Post -$0.30 EPS - July 27 at 10:33 PM logoAratana Therapeutics Announces Positive Results for AT-003 - July 27 at 6:17 AM logoAratana sniffs out new use for dog drug in cats - July 27 at 6:17 AM logoAratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on Wednesday - July 26 at 7:20 AM logoAratana Therapeutics, Inc. (PETX) Upgraded to "Hold" at ValuEngine - July 26 at 12:44 AM logoComparing Aratana Therapeutics (NASDAQ:PETX) & Zoetis (ZTS) - July 22 at 12:12 PM logoHead to Head Contrast: Phibro Animal Health Corporation (PAHC) & Aratana Therapeutics (PETX) - July 19 at 8:51 AM logoAratana Therapeutics to Report Second Quarter 2017 Financial Results - July 19 at 2:24 AM logoFinancial Survey: Aratana Therapeutics (NASDAQ:PETX) versus Zoetis (ZTS) - July 16 at 8:00 AM logoAratana Therapeutics, Inc. (PETX) Given Average Recommendation of "Buy" by Brokerages - July 14 at 3:19 PM logoHead to Head Review: Aratana Therapeutics (PETX) vs. Phibro Animal Health Corporation (PAHC) - July 9 at 10:26 AM logoETFs with exposure to Aratana Therapeutics, Inc. : July 7, 2017 - July 8 at 1:29 PM logoReviewing Phibro Animal Health Corporation (PAHC) & Aratana Therapeutics (NASDAQ:PETX) - July 5 at 6:36 PM logo$4.60 Million in Sales Expected for Aratana Therapeutics, Inc. (NASDAQ:PETX) This Quarter - July 5 at 11:33 AM logoAratana Therapeutics, Inc. (NASDAQ:PETX) Expected to Post Earnings of -$0.30 Per Share - July 3 at 6:28 PM logoFast 50: No. 1 Aratana Therapeutics - June 30 at 8:29 PM logoAratana Therapeutics (PETX) vs. Phibro Animal Health Corporation (PAHC) Head to Head Contrast - June 30 at 8:19 AM logoETFs with exposure to Aratana Therapeutics, Inc. : June 26, 2017 - June 27 at 7:19 AM logoAratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of "Buy" from Analysts - June 19 at 2:30 PM logoETFs with exposure to Aratana Therapeutics, Inc. : June 16, 2017 - June 16 at 8:11 PM logoAratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 11:30 PM logoJefferies Group LLC Analysts Give Aratana Therapeutics Inc (PETX) a $8.00 Price Target - June 11 at 9:02 AM logo$4.60 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter - June 9 at 1:04 PM logoShort Interest in Aratana Therapeutics Inc (PETX) Decreases By 7.8% - June 9 at 7:40 AM



Aratana Therapeutics (PETX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff